'Cell therapy without cells': Capstan raises $175M to test in vivo CAR-T
20 Mar 2024
Cell TherapyImmunotherapy
Laura Shawver pictures a world 10 years from now where cell therapies are replaced by in vivo CAR-T products. The goal is a cheaper-to-produce, less complex and more accessible cell therapy.
On Wednesday, her San Diego-based startup Capstan Therapeutics announced a $175 million Series B, with backing from six large pharma companies or their venture arms, including Johnson & Johnson Innovation (also known as JJDC), Bristol Myers Squibb, Eli Lilly, Leaps by Bayer, Novartis Venture Fund and Pfizer Ventures.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.